nodes	percent_of_prediction	percent_of_DWPC	metapath
Dinoprostone—CYP11A1—Cholecalciferol—psoriasis	0.127	0.16	CbGbCtD
Dinoprostone—SLCO3A1—Methotrexate—psoriasis	0.0728	0.0922	CbGbCtD
Dinoprostone—CYP11A1—Dexamethasone—psoriasis	0.0548	0.0694	CbGbCtD
Dinoprostone—SLCO1C1—Methotrexate—psoriasis	0.0465	0.0589	CbGbCtD
Dinoprostone—CYP19A1—Betamethasone—psoriasis	0.0438	0.0555	CbGbCtD
Dinoprostone—CYP1A2—Clobetasol propionate—psoriasis	0.041	0.0519	CbGbCtD
Dinoprostone—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0377	0.0478	CbGbCtD
Dinoprostone—SLCO1A2—Prednisolone—psoriasis	0.0338	0.0429	CbGbCtD
Dinoprostone—SLCO1A2—Hydrocortisone—psoriasis	0.0321	0.0406	CbGbCtD
Dinoprostone—SLCO1A2—Prednisone—psoriasis	0.032	0.0405	CbGbCtD
Dinoprostone—SLCO1A2—Cyclosporine—psoriasis	0.0303	0.0384	CbGbCtD
Dinoprostone—SLCO1B1—Cyclosporine—psoriasis	0.0286	0.0362	CbGbCtD
Dinoprostone—CYP19A1—Dexamethasone—psoriasis	0.0255	0.0323	CbGbCtD
Dinoprostone—SLC22A11—Methotrexate—psoriasis	0.024	0.0304	CbGbCtD
Dinoprostone—SLC22A7—Methotrexate—psoriasis	0.0229	0.029	CbGbCtD
Dinoprostone—ABCC4—Methotrexate—psoriasis	0.0223	0.0283	CbGbCtD
Dinoprostone—CYP1A2—Methoxsalen—psoriasis	0.0215	0.0272	CbGbCtD
Dinoprostone—SLCO1A2—Dexamethasone—psoriasis	0.02	0.0253	CbGbCtD
Dinoprostone—SLC22A6—Cyclosporine—psoriasis	0.0184	0.0233	CbGbCtD
Dinoprostone—SLCO1A2—Methotrexate—psoriasis	0.016	0.0203	CbGbCtD
Dinoprostone—SLCO1B1—Methotrexate—psoriasis	0.0151	0.0192	CbGbCtD
Dinoprostone—SLC22A8—Methotrexate—psoriasis	0.014	0.0177	CbGbCtD
Dinoprostone—SLC22A6—Methotrexate—psoriasis	0.00973	0.0123	CbGbCtD
Dinoprostone—Nausea—Acitretin—psoriasis	0.000237	0.00153	CcSEcCtD
Dinoprostone—Nausea—Fluocinolone Acetonide—psoriasis	0.000236	0.00153	CcSEcCtD
Dinoprostone—Paraesthesia—Mycophenolic acid—psoriasis	0.000236	0.00152	CcSEcCtD
Dinoprostone—Dyspnoea—Mycophenolic acid—psoriasis	0.000234	0.00151	CcSEcCtD
Dinoprostone—Hypersensitivity—Hydroxyurea—psoriasis	0.000231	0.00149	CcSEcCtD
Dinoprostone—Syncope—Mycophenolate mofetil—psoriasis	0.000228	0.00147	CcSEcCtD
Dinoprostone—Cough—Cyclosporine—psoriasis	0.000227	0.00147	CcSEcCtD
Dinoprostone—Asthenia—Hydroxyurea—psoriasis	0.000225	0.00145	CcSEcCtD
Dinoprostone—Hypertension—Cyclosporine—psoriasis	0.000225	0.00145	CcSEcCtD
Dinoprostone—Pain—Mycophenolic acid—psoriasis	0.000225	0.00145	CcSEcCtD
Dinoprostone—Arrhythmia—Triamcinolone—psoriasis	0.000223	0.00144	CcSEcCtD
Dinoprostone—Vision blurred—Prednisolone—psoriasis	0.000223	0.00144	CcSEcCtD
Dinoprostone—Loss of consciousness—Mycophenolate mofetil—psoriasis	0.000223	0.00144	CcSEcCtD
Dinoprostone—Myalgia—Cyclosporine—psoriasis	0.000222	0.00143	CcSEcCtD
Dinoprostone—Chest pain—Cyclosporine—psoriasis	0.000222	0.00143	CcSEcCtD
Dinoprostone—Arthralgia—Cyclosporine—psoriasis	0.000222	0.00143	CcSEcCtD
Dinoprostone—Cough—Mycophenolate mofetil—psoriasis	0.000222	0.00143	CcSEcCtD
Dinoprostone—Hypertension—Mycophenolate mofetil—psoriasis	0.000219	0.00142	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Prednisone—psoriasis	0.000217	0.0014	CcSEcCtD
Dinoprostone—Chest pain—Mycophenolate mofetil—psoriasis	0.000216	0.0014	CcSEcCtD
Dinoprostone—Arthralgia—Mycophenolate mofetil—psoriasis	0.000216	0.0014	CcSEcCtD
Dinoprostone—Myalgia—Mycophenolate mofetil—psoriasis	0.000216	0.0014	CcSEcCtD
Dinoprostone—Myocardial infarction—Prednisone—psoriasis	0.000216	0.00139	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000215	0.00139	CcSEcCtD
Dinoprostone—Diarrhoea—Hydroxyurea—psoriasis	0.000214	0.00139	CcSEcCtD
Dinoprostone—Anaphylactic shock—Cyclosporine—psoriasis	0.000212	0.00137	CcSEcCtD
Dinoprostone—Syncope—Prednisolone—psoriasis	0.000212	0.00137	CcSEcCtD
Dinoprostone—Back pain—Triamcinolone—psoriasis	0.000211	0.00136	CcSEcCtD
Dinoprostone—Loss of consciousness—Prednisolone—psoriasis	0.000208	0.00134	CcSEcCtD
Dinoprostone—Abdominal pain—Mycophenolic acid—psoriasis	0.000208	0.00134	CcSEcCtD
Dinoprostone—Body temperature increased—Mycophenolic acid—psoriasis	0.000208	0.00134	CcSEcCtD
Dinoprostone—Syncope—Hydrocortisone—psoriasis	0.000207	0.00134	CcSEcCtD
Dinoprostone—Dizziness—Hydroxyurea—psoriasis	0.000207	0.00134	CcSEcCtD
Dinoprostone—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000207	0.00134	CcSEcCtD
Dinoprostone—Asthma—Methotrexate—psoriasis	0.000206	0.00133	CcSEcCtD
Dinoprostone—Angiopathy—Dexamethasone—psoriasis	0.000206	0.00133	CcSEcCtD
Dinoprostone—Angiopathy—Betamethasone—psoriasis	0.000206	0.00133	CcSEcCtD
Dinoprostone—Hyperhidrosis—Cyclosporine—psoriasis	0.000205	0.00133	CcSEcCtD
Dinoprostone—Hypertension—Prednisolone—psoriasis	0.000204	0.00132	CcSEcCtD
Dinoprostone—Shock—Mycophenolate mofetil—psoriasis	0.000204	0.00132	CcSEcCtD
Dinoprostone—Loss of consciousness—Hydrocortisone—psoriasis	0.000203	0.00131	CcSEcCtD
Dinoprostone—Arrhythmia—Dexamethasone—psoriasis	0.000203	0.00131	CcSEcCtD
Dinoprostone—Arrhythmia—Betamethasone—psoriasis	0.000203	0.00131	CcSEcCtD
Dinoprostone—Tachycardia—Mycophenolate mofetil—psoriasis	0.000202	0.00131	CcSEcCtD
Dinoprostone—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.0002	0.00129	CcSEcCtD
Dinoprostone—Hypertension—Hydrocortisone—psoriasis	0.0002	0.00129	CcSEcCtD
Dinoprostone—Vomiting—Hydroxyurea—psoriasis	0.000199	0.00129	CcSEcCtD
Dinoprostone—Rash—Hydroxyurea—psoriasis	0.000198	0.00128	CcSEcCtD
Dinoprostone—Dermatitis—Hydroxyurea—psoriasis	0.000197	0.00128	CcSEcCtD
Dinoprostone—Myalgia—Hydrocortisone—psoriasis	0.000197	0.00127	CcSEcCtD
Dinoprostone—Headache—Hydroxyurea—psoriasis	0.000196	0.00127	CcSEcCtD
Dinoprostone—Syncope—Triamcinolone—psoriasis	0.000195	0.00126	CcSEcCtD
Dinoprostone—Hypotension—Mycophenolate mofetil—psoriasis	0.000194	0.00125	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000194	0.00125	CcSEcCtD
Dinoprostone—Anaphylactic shock—Prednisolone—psoriasis	0.000193	0.00125	CcSEcCtD
Dinoprostone—Loss of consciousness—Triamcinolone—psoriasis	0.000191	0.00124	CcSEcCtD
Dinoprostone—Paraesthesia—Cyclosporine—psoriasis	0.000191	0.00123	CcSEcCtD
Dinoprostone—Shock—Prednisolone—psoriasis	0.00019	0.00123	CcSEcCtD
Dinoprostone—Cough—Triamcinolone—psoriasis	0.00019	0.00123	CcSEcCtD
Dinoprostone—Dyspnoea—Cyclosporine—psoriasis	0.000189	0.00122	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000189	0.00122	CcSEcCtD
Dinoprostone—Anaphylactic shock—Hydrocortisone—psoriasis	0.000189	0.00122	CcSEcCtD
Dinoprostone—Tachycardia—Prednisolone—psoriasis	0.000189	0.00122	CcSEcCtD
Dinoprostone—Asthenia—Mycophenolic acid—psoriasis	0.000188	0.00122	CcSEcCtD
Dinoprostone—Hypertension—Triamcinolone—psoriasis	0.000188	0.00121	CcSEcCtD
Dinoprostone—Hyperhidrosis—Prednisolone—psoriasis	0.000187	0.00121	CcSEcCtD
Dinoprostone—Nausea—Hydroxyurea—psoriasis	0.000186	0.0012	CcSEcCtD
Dinoprostone—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000186	0.0012	CcSEcCtD
Dinoprostone—Shock—Hydrocortisone—psoriasis	0.000186	0.0012	CcSEcCtD
Dinoprostone—Myalgia—Triamcinolone—psoriasis	0.000185	0.0012	CcSEcCtD
Dinoprostone—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000185	0.00119	CcSEcCtD
Dinoprostone—Tachycardia—Hydrocortisone—psoriasis	0.000184	0.00119	CcSEcCtD
Dinoprostone—Flushing—Prednisone—psoriasis	0.000183	0.00119	CcSEcCtD
Dinoprostone—Hyperhidrosis—Hydrocortisone—psoriasis	0.000182	0.00118	CcSEcCtD
Dinoprostone—Pain—Cyclosporine—psoriasis	0.000182	0.00117	CcSEcCtD
Dinoprostone—Diarrhoea—Mycophenolic acid—psoriasis	0.00018	0.00116	CcSEcCtD
Dinoprostone—Angiopathy—Prednisone—psoriasis	0.000179	0.00116	CcSEcCtD
Dinoprostone—Immune system disorder—Prednisone—psoriasis	0.000179	0.00115	CcSEcCtD
Dinoprostone—Anaphylactic shock—Triamcinolone—psoriasis	0.000178	0.00115	CcSEcCtD
Dinoprostone—Syncope—Betamethasone—psoriasis	0.000177	0.00114	CcSEcCtD
Dinoprostone—Syncope—Dexamethasone—psoriasis	0.000177	0.00114	CcSEcCtD
Dinoprostone—Pain—Mycophenolate mofetil—psoriasis	0.000177	0.00114	CcSEcCtD
Dinoprostone—Arrhythmia—Prednisone—psoriasis	0.000177	0.00114	CcSEcCtD
Dinoprostone—Hypotension—Hydrocortisone—psoriasis	0.000176	0.00114	CcSEcCtD
Dinoprostone—Shock—Triamcinolone—psoriasis	0.000175	0.00113	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Cyclosporine—psoriasis	0.000174	0.00112	CcSEcCtD
Dinoprostone—Loss of consciousness—Betamethasone—psoriasis	0.000174	0.00112	CcSEcCtD
Dinoprostone—Loss of consciousness—Dexamethasone—psoriasis	0.000174	0.00112	CcSEcCtD
Dinoprostone—Dizziness—Mycophenolic acid—psoriasis	0.000174	0.00112	CcSEcCtD
Dinoprostone—Paraesthesia—Prednisolone—psoriasis	0.000174	0.00112	CcSEcCtD
Dinoprostone—Tachycardia—Triamcinolone—psoriasis	0.000173	0.00112	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000172	0.00111	CcSEcCtD
Dinoprostone—Hyperhidrosis—Triamcinolone—psoriasis	0.000172	0.00111	CcSEcCtD
Dinoprostone—Hypertension—Betamethasone—psoriasis	0.000171	0.0011	CcSEcCtD
Dinoprostone—Hypertension—Dexamethasone—psoriasis	0.000171	0.0011	CcSEcCtD
Dinoprostone—Paraesthesia—Hydrocortisone—psoriasis	0.000169	0.00109	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000169	0.00109	CcSEcCtD
Dinoprostone—Myalgia—Dexamethasone—psoriasis	0.000168	0.00109	CcSEcCtD
Dinoprostone—Myalgia—Betamethasone—psoriasis	0.000168	0.00109	CcSEcCtD
Dinoprostone—Abdominal pain—Cyclosporine—psoriasis	0.000168	0.00108	CcSEcCtD
Dinoprostone—Body temperature increased—Cyclosporine—psoriasis	0.000168	0.00108	CcSEcCtD
Dinoprostone—Vomiting—Mycophenolic acid—psoriasis	0.000167	0.00108	CcSEcCtD
Dinoprostone—Rash—Mycophenolic acid—psoriasis	0.000166	0.00107	CcSEcCtD
Dinoprostone—Dermatitis—Mycophenolic acid—psoriasis	0.000165	0.00107	CcSEcCtD
Dinoprostone—Pain—Prednisolone—psoriasis	0.000165	0.00107	CcSEcCtD
Dinoprostone—Headache—Mycophenolic acid—psoriasis	0.000164	0.00106	CcSEcCtD
Dinoprostone—Pharyngitis—Methotrexate—psoriasis	0.000164	0.00106	CcSEcCtD
Dinoprostone—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000164	0.00106	CcSEcCtD
Dinoprostone—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000164	0.00106	CcSEcCtD
Dinoprostone—Vision blurred—Prednisone—psoriasis	0.000162	0.00105	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000162	0.00105	CcSEcCtD
Dinoprostone—Pain—Hydrocortisone—psoriasis	0.000161	0.00104	CcSEcCtD
Dinoprostone—Anaphylactic shock—Betamethasone—psoriasis	0.000161	0.00104	CcSEcCtD
Dinoprostone—Anaphylactic shock—Dexamethasone—psoriasis	0.000161	0.00104	CcSEcCtD
Dinoprostone—Paraesthesia—Triamcinolone—psoriasis	0.00016	0.00103	CcSEcCtD
Dinoprostone—Shock—Betamethasone—psoriasis	0.000159	0.00102	CcSEcCtD
Dinoprostone—Shock—Dexamethasone—psoriasis	0.000159	0.00102	CcSEcCtD
Dinoprostone—Dyspnoea—Triamcinolone—psoriasis	0.000158	0.00102	CcSEcCtD
Dinoprostone—Tachycardia—Betamethasone—psoriasis	0.000157	0.00102	CcSEcCtD
Dinoprostone—Tachycardia—Dexamethasone—psoriasis	0.000157	0.00102	CcSEcCtD
Dinoprostone—Hypersensitivity—Cyclosporine—psoriasis	0.000156	0.00101	CcSEcCtD
Dinoprostone—Nausea—Mycophenolic acid—psoriasis	0.000156	0.00101	CcSEcCtD
Dinoprostone—Hyperhidrosis—Dexamethasone—psoriasis	0.000156	0.00101	CcSEcCtD
Dinoprostone—Hyperhidrosis—Betamethasone—psoriasis	0.000156	0.00101	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000154	0.000997	CcSEcCtD
Dinoprostone—Syncope—Prednisone—psoriasis	0.000154	0.000997	CcSEcCtD
Dinoprostone—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000153	0.000986	CcSEcCtD
Dinoprostone—Asthenia—Cyclosporine—psoriasis	0.000152	0.000984	CcSEcCtD
Dinoprostone—Pain—Triamcinolone—psoriasis	0.000152	0.000982	CcSEcCtD
Dinoprostone—Loss of consciousness—Prednisone—psoriasis	0.000151	0.000977	CcSEcCtD
Dinoprostone—Hypotension—Dexamethasone—psoriasis	0.000151	0.000973	CcSEcCtD
Dinoprostone—Hypotension—Betamethasone—psoriasis	0.000151	0.000973	CcSEcCtD
Dinoprostone—Angiopathy—Methotrexate—psoriasis	0.00015	0.000968	CcSEcCtD
Dinoprostone—Immune system disorder—Methotrexate—psoriasis	0.000149	0.000964	CcSEcCtD
Dinoprostone—Abdominal pain—Hydrocortisone—psoriasis	0.000149	0.000964	CcSEcCtD
Dinoprostone—Body temperature increased—Hydrocortisone—psoriasis	0.000149	0.000964	CcSEcCtD
Dinoprostone—Asthenia—Mycophenolate mofetil—psoriasis	0.000149	0.00096	CcSEcCtD
Dinoprostone—Hypertension—Prednisone—psoriasis	0.000149	0.00096	CcSEcCtD
Dinoprostone—Chills—Methotrexate—psoriasis	0.000148	0.000958	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000147	0.000949	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000147	0.000949	CcSEcCtD
Dinoprostone—Myalgia—Prednisone—psoriasis	0.000147	0.000946	CcSEcCtD
Dinoprostone—Arthralgia—Prednisone—psoriasis	0.000147	0.000946	CcSEcCtD
Dinoprostone—Diarrhoea—Cyclosporine—psoriasis	0.000145	0.000939	CcSEcCtD
Dinoprostone—Paraesthesia—Dexamethasone—psoriasis	0.000145	0.000935	CcSEcCtD
Dinoprostone—Paraesthesia—Betamethasone—psoriasis	0.000145	0.000935	CcSEcCtD
Dinoprostone—Hypersensitivity—Prednisolone—psoriasis	0.000142	0.00092	CcSEcCtD
Dinoprostone—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000142	0.000916	CcSEcCtD
Dinoprostone—Body temperature increased—Triamcinolone—psoriasis	0.000141	0.000908	CcSEcCtD
Dinoprostone—Dizziness—Cyclosporine—psoriasis	0.00014	0.000907	CcSEcCtD
Dinoprostone—Anaphylactic shock—Prednisone—psoriasis	0.00014	0.000907	CcSEcCtD
Dinoprostone—Back pain—Methotrexate—psoriasis	0.000139	0.000899	CcSEcCtD
Dinoprostone—Hypersensitivity—Hydrocortisone—psoriasis	0.000139	0.000898	CcSEcCtD
Dinoprostone—Shock—Prednisone—psoriasis	0.000138	0.000893	CcSEcCtD
Dinoprostone—Pain—Dexamethasone—psoriasis	0.000138	0.000891	CcSEcCtD
Dinoprostone—Pain—Betamethasone—psoriasis	0.000138	0.000891	CcSEcCtD
Dinoprostone—Tachycardia—Prednisone—psoriasis	0.000137	0.000885	CcSEcCtD
Dinoprostone—Dizziness—Mycophenolate mofetil—psoriasis	0.000137	0.000885	CcSEcCtD
Dinoprostone—Hyperhidrosis—Prednisone—psoriasis	0.000136	0.000877	CcSEcCtD
Dinoprostone—Vision blurred—Methotrexate—psoriasis	0.000136	0.000876	CcSEcCtD
Dinoprostone—Asthenia—Hydrocortisone—psoriasis	0.000135	0.000875	CcSEcCtD
Dinoprostone—Vomiting—Cyclosporine—psoriasis	0.000135	0.000872	CcSEcCtD
Dinoprostone—Rash—Cyclosporine—psoriasis	0.000134	0.000865	CcSEcCtD
Dinoprostone—Dermatitis—Cyclosporine—psoriasis	0.000134	0.000864	CcSEcCtD
Dinoprostone—Headache—Cyclosporine—psoriasis	0.000133	0.00086	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Betamethasone—psoriasis	0.000132	0.000852	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Dexamethasone—psoriasis	0.000132	0.000852	CcSEcCtD
Dinoprostone—Vomiting—Mycophenolate mofetil—psoriasis	0.000132	0.000851	CcSEcCtD
Dinoprostone—Hypersensitivity—Triamcinolone—psoriasis	0.000131	0.000846	CcSEcCtD
Dinoprostone—Rash—Mycophenolate mofetil—psoriasis	0.000131	0.000844	CcSEcCtD
Dinoprostone—Dermatitis—Mycophenolate mofetil—psoriasis	0.000131	0.000843	CcSEcCtD
Dinoprostone—Headache—Mycophenolate mofetil—psoriasis	0.00013	0.000838	CcSEcCtD
Dinoprostone—Diarrhoea—Hydrocortisone—psoriasis	0.000129	0.000834	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Prednisone—psoriasis	0.000128	0.000827	CcSEcCtD
Dinoprostone—Dizziness—Prednisolone—psoriasis	0.000128	0.000826	CcSEcCtD
Dinoprostone—Asthenia—Triamcinolone—psoriasis	0.000128	0.000824	CcSEcCtD
Dinoprostone—Body temperature increased—Dexamethasone—psoriasis	0.000127	0.000824	CcSEcCtD
Dinoprostone—Abdominal pain—Dexamethasone—psoriasis	0.000127	0.000824	CcSEcCtD
Dinoprostone—Abdominal pain—Betamethasone—psoriasis	0.000127	0.000824	CcSEcCtD
Dinoprostone—Body temperature increased—Betamethasone—psoriasis	0.000127	0.000824	CcSEcCtD
Dinoprostone—Nausea—Cyclosporine—psoriasis	0.000126	0.000815	CcSEcCtD
Dinoprostone—Paraesthesia—Prednisone—psoriasis	0.000126	0.000815	CcSEcCtD
Dinoprostone—Cough—Methotrexate—psoriasis	0.000125	0.000811	CcSEcCtD
Dinoprostone—Dizziness—Hydrocortisone—psoriasis	0.000125	0.000806	CcSEcCtD
Dinoprostone—Nausea—Mycophenolate mofetil—psoriasis	0.000123	0.000795	CcSEcCtD
Dinoprostone—Chest pain—Methotrexate—psoriasis	0.000122	0.000791	CcSEcCtD
Dinoprostone—Myalgia—Methotrexate—psoriasis	0.000122	0.000791	CcSEcCtD
Dinoprostone—Arthralgia—Methotrexate—psoriasis	0.000122	0.000791	CcSEcCtD
Dinoprostone—Rash—Prednisolone—psoriasis	0.000122	0.000787	CcSEcCtD
Dinoprostone—Dermatitis—Prednisolone—psoriasis	0.000122	0.000786	CcSEcCtD
Dinoprostone—Headache—Prednisolone—psoriasis	0.000121	0.000782	CcSEcCtD
Dinoprostone—Vomiting—Hydrocortisone—psoriasis	0.00012	0.000775	CcSEcCtD
Dinoprostone—Rash—Hydrocortisone—psoriasis	0.000119	0.000769	CcSEcCtD
Dinoprostone—Dermatitis—Hydrocortisone—psoriasis	0.000119	0.000768	CcSEcCtD
Dinoprostone—Headache—Hydrocortisone—psoriasis	0.000118	0.000764	CcSEcCtD
Dinoprostone—Dizziness—Triamcinolone—psoriasis	0.000118	0.000759	CcSEcCtD
Dinoprostone—Anaphylactic shock—Methotrexate—psoriasis	0.000117	0.000758	CcSEcCtD
Dinoprostone—Asthenia—Betamethasone—psoriasis	0.000116	0.000747	CcSEcCtD
Dinoprostone—Asthenia—Dexamethasone—psoriasis	0.000116	0.000747	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Prednisone—psoriasis	0.000115	0.000742	CcSEcCtD
Dinoprostone—Nausea—Prednisolone—psoriasis	0.000115	0.000742	CcSEcCtD
Dinoprostone—Hyperhidrosis—Methotrexate—psoriasis	0.000113	0.000733	CcSEcCtD
Dinoprostone—Vomiting—Triamcinolone—psoriasis	0.000113	0.00073	CcSEcCtD
Dinoprostone—Nausea—Hydrocortisone—psoriasis	0.000112	0.000724	CcSEcCtD
Dinoprostone—Rash—Triamcinolone—psoriasis	0.000112	0.000724	CcSEcCtD
Dinoprostone—Dermatitis—Triamcinolone—psoriasis	0.000112	0.000723	CcSEcCtD
Dinoprostone—Headache—Triamcinolone—psoriasis	0.000111	0.000719	CcSEcCtD
Dinoprostone—Abdominal pain—Prednisone—psoriasis	0.000111	0.000717	CcSEcCtD
Dinoprostone—Body temperature increased—Prednisone—psoriasis	0.000111	0.000717	CcSEcCtD
Dinoprostone—Diarrhoea—Dexamethasone—psoriasis	0.00011	0.000713	CcSEcCtD
Dinoprostone—Diarrhoea—Betamethasone—psoriasis	0.00011	0.000713	CcSEcCtD
Dinoprostone—Hypotension—Methotrexate—psoriasis	0.00011	0.000708	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000107	0.000691	CcSEcCtD
Dinoprostone—Dizziness—Betamethasone—psoriasis	0.000107	0.000689	CcSEcCtD
Dinoprostone—Dizziness—Dexamethasone—psoriasis	0.000107	0.000689	CcSEcCtD
Dinoprostone—Nausea—Triamcinolone—psoriasis	0.000106	0.000682	CcSEcCtD
Dinoprostone—Paraesthesia—Methotrexate—psoriasis	0.000105	0.000681	CcSEcCtD
Dinoprostone—Dyspnoea—Methotrexate—psoriasis	0.000105	0.000676	CcSEcCtD
Dinoprostone—Hypersensitivity—Prednisone—psoriasis	0.000103	0.000668	CcSEcCtD
Dinoprostone—Vomiting—Dexamethasone—psoriasis	0.000103	0.000662	CcSEcCtD
Dinoprostone—Vomiting—Betamethasone—psoriasis	0.000103	0.000662	CcSEcCtD
Dinoprostone—Rash—Dexamethasone—psoriasis	0.000102	0.000657	CcSEcCtD
Dinoprostone—Rash—Betamethasone—psoriasis	0.000102	0.000657	CcSEcCtD
Dinoprostone—Dermatitis—Betamethasone—psoriasis	0.000102	0.000656	CcSEcCtD
Dinoprostone—Dermatitis—Dexamethasone—psoriasis	0.000102	0.000656	CcSEcCtD
Dinoprostone—Headache—Betamethasone—psoriasis	0.000101	0.000653	CcSEcCtD
Dinoprostone—Headache—Dexamethasone—psoriasis	0.000101	0.000653	CcSEcCtD
Dinoprostone—Asthenia—Prednisone—psoriasis	0.000101	0.000651	CcSEcCtD
Dinoprostone—Pain—Methotrexate—psoriasis	0.0001	0.000648	CcSEcCtD
Dinoprostone—Diarrhoea—Prednisone—psoriasis	9.61e-05	0.000621	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Methotrexate—psoriasis	9.6e-05	0.00062	CcSEcCtD
Dinoprostone—Nausea—Dexamethasone—psoriasis	9.58e-05	0.000619	CcSEcCtD
Dinoprostone—Nausea—Betamethasone—psoriasis	9.58e-05	0.000619	CcSEcCtD
Dinoprostone—PTGFR—Signaling Pathways—HCAR2—psoriasis	9.39e-05	0.00169	CbGpPWpGaD
Dinoprostone—ABCC5—Transmembrane transport of small molecules—CP—psoriasis	9.34e-05	0.00168	CbGpPWpGaD
Dinoprostone—SLCO2B1—Transmembrane transport of small molecules—CARM1—psoriasis	9.32e-05	0.00168	CbGpPWpGaD
Dinoprostone—Dizziness—Prednisone—psoriasis	9.29e-05	0.0006	CcSEcCtD
Dinoprostone—Body temperature increased—Methotrexate—psoriasis	9.28e-05	0.000599	CcSEcCtD
Dinoprostone—Abdominal pain—Methotrexate—psoriasis	9.28e-05	0.000599	CcSEcCtD
Dinoprostone—SLC22A2—SLC-mediated transmembrane transport—CP—psoriasis	9.25e-05	0.00166	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—HCAR2—psoriasis	9.19e-05	0.00165	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—HCAR2—psoriasis	9.19e-05	0.00165	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—CCL20—psoriasis	9.09e-05	0.00164	CbGpPWpGaD
Dinoprostone—Vomiting—Prednisone—psoriasis	8.93e-05	0.000577	CcSEcCtD
Dinoprostone—ABCC5—Transmembrane transport of small molecules—CARM1—psoriasis	8.91e-05	0.0016	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—CCL20—psoriasis	8.9e-05	0.0016	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—CCL20—psoriasis	8.9e-05	0.0016	CbGpPWpGaD
Dinoprostone—Rash—Prednisone—psoriasis	8.86e-05	0.000572	CcSEcCtD
Dinoprostone—SLC22A11—Transmembrane transport of small molecules—CP—psoriasis	8.85e-05	0.00159	CbGpPWpGaD
Dinoprostone—Dermatitis—Prednisone—psoriasis	8.85e-05	0.000572	CcSEcCtD
Dinoprostone—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	8.85e-05	0.00159	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—NDUFA5—psoriasis	8.8e-05	0.00158	CbGpPWpGaD
Dinoprostone—Headache—Prednisone—psoriasis	8.8e-05	0.000568	CcSEcCtD
Dinoprostone—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	8.66e-05	0.00156	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.65e-05	0.00156	CbGpPWpGaD
Dinoprostone—Hypersensitivity—Methotrexate—psoriasis	8.65e-05	0.000559	CcSEcCtD
Dinoprostone—SLC22A1—SLC-mediated transmembrane transport—CP—psoriasis	8.62e-05	0.00155	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—CCL20—psoriasis	8.6e-05	0.00155	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—CYP2S1—psoriasis	8.54e-05	0.00154	CbGpPWpGaD
Dinoprostone—HPGDS—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	8.45e-05	0.00152	CbGpPWpGaD
Dinoprostone—SLC22A11—Transmembrane transport of small molecules—CARM1—psoriasis	8.45e-05	0.00152	CbGpPWpGaD
Dinoprostone—Asthenia—Methotrexate—psoriasis	8.42e-05	0.000544	CcSEcCtD
Dinoprostone—Nausea—Prednisone—psoriasis	8.34e-05	0.000539	CcSEcCtD
Dinoprostone—PTGER2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	8.26e-05	0.00149	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—CCL20—psoriasis	8.25e-05	0.00149	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.21e-05	0.00148	CbGpPWpGaD
Dinoprostone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.15e-05	0.00147	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TAGAP—psoriasis	8.14e-05	0.00147	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—CCL20—psoriasis	8.08e-05	0.00145	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—CCL20—psoriasis	8.08e-05	0.00145	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—CARM1—psoriasis	8.06e-05	0.00145	CbGpPWpGaD
Dinoprostone—ABCC4—Platelet degranulation—VEGFA—psoriasis	8.05e-05	0.00145	CbGpPWpGaD
Dinoprostone—SLC22A7—Transmembrane transport of small molecules—CP—psoriasis	8.03e-05	0.00145	CbGpPWpGaD
Dinoprostone—Diarrhoea—Methotrexate—psoriasis	8.03e-05	0.000519	CcSEcCtD
Dinoprostone—PTGIR—Signaling Pathways—TAGAP—psoriasis	7.97e-05	0.00143	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TAGAP—psoriasis	7.97e-05	0.00143	CbGpPWpGaD
Dinoprostone—Dizziness—Methotrexate—psoriasis	7.76e-05	0.000501	CcSEcCtD
Dinoprostone—ABCC4—Hemostasis—ITGAL—psoriasis	7.74e-05	0.00139	CbGpPWpGaD
Dinoprostone—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	7.67e-05	0.00138	CbGpPWpGaD
Dinoprostone—SLC22A7—Transmembrane transport of small molecules—CARM1—psoriasis	7.66e-05	0.00138	CbGpPWpGaD
Dinoprostone—PTGER4—GPCR ligand binding—CXCL8—psoriasis	7.66e-05	0.00138	CbGpPWpGaD
Dinoprostone—PTGER3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	7.63e-05	0.00137	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.53e-05	0.00136	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—CYP2S1—psoriasis	7.48e-05	0.00135	CbGpPWpGaD
Dinoprostone—Vomiting—Methotrexate—psoriasis	7.46e-05	0.000482	CcSEcCtD
Dinoprostone—Rash—Methotrexate—psoriasis	7.4e-05	0.000478	CcSEcCtD
Dinoprostone—Dermatitis—Methotrexate—psoriasis	7.39e-05	0.000478	CcSEcCtD
Dinoprostone—Headache—Methotrexate—psoriasis	7.35e-05	0.000475	CcSEcCtD
Dinoprostone—PTGER2—Signaling Pathways—CCL20—psoriasis	7.06e-05	0.00127	CbGpPWpGaD
Dinoprostone—Nausea—Methotrexate—psoriasis	6.97e-05	0.00045	CcSEcCtD
Dinoprostone—SLC22A8—Transmembrane transport of small molecules—CP—psoriasis	6.75e-05	0.00122	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CCL20—psoriasis	6.52e-05	0.00117	CbGpPWpGaD
Dinoprostone—ABCC4—Transmembrane transport of small molecules—CP—psoriasis	6.47e-05	0.00117	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—NDUFA5—psoriasis	6.45e-05	0.00116	CbGpPWpGaD
Dinoprostone—SLC22A8—Transmembrane transport of small molecules—CARM1—psoriasis	6.44e-05	0.00116	CbGpPWpGaD
Dinoprostone—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	6.32e-05	0.00114	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR ligand binding—CXCL8—psoriasis	6.29e-05	0.00113	CbGpPWpGaD
Dinoprostone—ABCC4—Transmembrane transport of small molecules—CARM1—psoriasis	6.18e-05	0.00111	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.01e-05	0.00108	CbGpPWpGaD
Dinoprostone—SLCO1A2—Transmembrane transport of small molecules—CP—psoriasis	6e-05	0.00108	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—NDUFA5—psoriasis	5.83e-05	0.00105	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR ligand binding—CXCL8—psoriasis	5.81e-05	0.00105	CbGpPWpGaD
Dinoprostone—SLCO1A2—Transmembrane transport of small molecules—CARM1—psoriasis	5.72e-05	0.00103	CbGpPWpGaD
Dinoprostone—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.7e-05	0.00103	CbGpPWpGaD
Dinoprostone—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	5.64e-05	0.00101	CbGpPWpGaD
Dinoprostone—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.58e-05	0.00101	CbGpPWpGaD
Dinoprostone—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.58e-05	0.00101	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—NDUFA5—psoriasis	5.52e-05	0.000993	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—CYP2S1—psoriasis	5.49e-05	0.000988	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.44e-05	0.000979	CbGpPWpGaD
Dinoprostone—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	5.38e-05	0.000968	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—NOS2—psoriasis	5.33e-05	0.00096	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.25e-05	0.000946	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.14e-05	0.000926	CbGpPWpGaD
Dinoprostone—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	5.13e-05	0.000923	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—NDUFA5—psoriasis	5.06e-05	0.00091	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—CAT—psoriasis	4.96e-05	0.000893	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—CYP2S1—psoriasis	4.96e-05	0.000893	CbGpPWpGaD
Dinoprostone—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	4.89e-05	0.000881	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CCL20—psoriasis	4.88e-05	0.000878	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CCL20—psoriasis	4.77e-05	0.000859	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CCL20—psoriasis	4.77e-05	0.000859	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—SOCS1—psoriasis	4.74e-05	0.000853	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—NDUFA5—psoriasis	4.71e-05	0.000848	CbGpPWpGaD
Dinoprostone—SLC22A2—Transmembrane transport of small molecules—CP—psoriasis	4.7e-05	0.000846	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—CYP2S1—psoriasis	4.69e-05	0.000845	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—JUN—psoriasis	4.64e-05	0.000835	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.54e-05	0.000817	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—TYK2—psoriasis	4.52e-05	0.000813	CbGpPWpGaD
Dinoprostone—SLC22A2—Transmembrane transport of small molecules—CARM1—psoriasis	4.48e-05	0.000807	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	4.47e-05	0.000804	CbGpPWpGaD
Dinoprostone—SLC22A1—Transmembrane transport of small molecules—CP—psoriasis	4.38e-05	0.000789	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.37e-05	0.000787	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR ligand binding—CXCL8—psoriasis	4.34e-05	0.000782	CbGpPWpGaD
Dinoprostone—PTGER4—GPCR downstream signaling—CXCL8—psoriasis	4.33e-05	0.00078	CbGpPWpGaD
Dinoprostone—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	4.33e-05	0.000779	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—CYP2S1—psoriasis	4.3e-05	0.000774	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR ligand binding—CXCL8—psoriasis	4.25e-05	0.000765	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR ligand binding—CXCL8—psoriasis	4.25e-05	0.000765	CbGpPWpGaD
Dinoprostone—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	4.23e-05	0.000763	CbGpPWpGaD
Dinoprostone—SLC22A1—Transmembrane transport of small molecules—CARM1—psoriasis	4.18e-05	0.000752	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—CARM1—psoriasis	4.17e-05	0.000751	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	4.05e-05	0.00073	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—CYP2S1—psoriasis	4.01e-05	0.000721	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.97e-05	0.000714	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—CXCL8—psoriasis	3.93e-05	0.000708	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.92e-05	0.000706	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—SOCS1—psoriasis	3.89e-05	0.000701	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—APOE—psoriasis	3.85e-05	0.000694	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—TYK2—psoriasis	3.71e-05	0.000668	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—CARM1—psoriasis	3.65e-05	0.000658	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—SOCS1—psoriasis	3.59e-05	0.000646	CbGpPWpGaD
Dinoprostone—ABCC4—Platelet activation, signaling and aggregation—VEGFA—psoriasis	3.57e-05	0.000643	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR downstream signaling—CXCL8—psoriasis	3.56e-05	0.00064	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—APOE—psoriasis	3.5e-05	0.00063	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—LEP—psoriasis	3.5e-05	0.00063	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—TYK2—psoriasis	3.42e-05	0.000616	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.42e-05	0.000615	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.4e-05	0.000612	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.4e-05	0.000612	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—PPARG—psoriasis	3.36e-05	0.000604	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR downstream signaling—CXCL8—psoriasis	3.28e-05	0.000591	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—NFKBIA—psoriasis	3.26e-05	0.000587	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—CXCL8—psoriasis	3.23e-05	0.000582	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—NOS2—psoriasis	3.18e-05	0.000572	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—VEGFA—psoriasis	3.09e-05	0.000556	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—TP53—psoriasis	3.06e-05	0.000551	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—CXCL8—psoriasis	2.98e-05	0.000537	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.87e-05	0.000518	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—LEP—psoriasis	2.87e-05	0.000517	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—APOE—psoriasis	2.87e-05	0.000517	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—SOCS1—psoriasis	2.68e-05	0.000483	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—CARM1—psoriasis	2.68e-05	0.000482	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—NFKBIA—psoriasis	2.68e-05	0.000482	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—TYK2—psoriasis	2.67e-05	0.00048	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—APOE—psoriasis	2.65e-05	0.000477	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—LEP—psoriasis	2.65e-05	0.000477	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—SOCS1—psoriasis	2.63e-05	0.000473	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—SOCS1—psoriasis	2.63e-05	0.000473	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.6e-05	0.000468	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—CAT—psoriasis	2.57e-05	0.000462	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—TYK2—psoriasis	2.56e-05	0.000461	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—HLA-A—psoriasis	2.55e-05	0.000459	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—TYK2—psoriasis	2.51e-05	0.000451	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—TYK2—psoriasis	2.51e-05	0.000451	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.5e-05	0.000451	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—NFKBIA—psoriasis	2.47e-05	0.000445	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.46e-05	0.000443	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—CXCL8—psoriasis	2.45e-05	0.000442	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—CARM1—psoriasis	2.42e-05	0.000436	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—CXCL8—psoriasis	2.4e-05	0.000433	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—CXCL8—psoriasis	2.4e-05	0.000433	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—APOE—psoriasis	2.38e-05	0.000429	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—TP53—psoriasis	2.33e-05	0.00042	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—CXCL8—psoriasis	2.32e-05	0.000418	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—CARM1—psoriasis	2.29e-05	0.000413	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.26e-05	0.000408	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—CAT—psoriasis	2.25e-05	0.000405	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—CXCL8—psoriasis	2.23e-05	0.000401	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—NOS2—psoriasis	2.22e-05	0.0004	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—IL6—psoriasis	2.21e-05	0.000398	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—NDUFA5—psoriasis	2.2e-05	0.000397	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—TYK2—psoriasis	2.19e-05	0.000395	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—CXCL8—psoriasis	2.18e-05	0.000393	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—CXCL8—psoriasis	2.18e-05	0.000393	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—JUN—psoriasis	2.16e-05	0.000389	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.14e-05	0.000386	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—CARM1—psoriasis	2.1e-05	0.000378	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—NFKB1—psoriasis	2.08e-05	0.000374	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.06e-05	0.00037	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—TYK2—psoriasis	2.02e-05	0.000364	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—APOE—psoriasis	1.99e-05	0.000359	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—LEP—psoriasis	1.98e-05	0.000357	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—APOE—psoriasis	1.98e-05	0.000357	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—CARM1—psoriasis	1.96e-05	0.000352	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—APOE—psoriasis	1.94e-05	0.000349	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—LEP—psoriasis	1.94e-05	0.000349	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—LEP—psoriasis	1.94e-05	0.000349	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—APOE—psoriasis	1.94e-05	0.000349	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CXCL8—psoriasis	1.91e-05	0.000344	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—VEGFA—psoriasis	1.89e-05	0.00034	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CYP2S1—psoriasis	1.87e-05	0.000338	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—STAT3—psoriasis	1.87e-05	0.000336	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—NFKBIA—psoriasis	1.85e-05	0.000332	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—VEGFA—psoriasis	1.84e-05	0.000331	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—TYK2—psoriasis	1.82e-05	0.000327	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—IL6—psoriasis	1.81e-05	0.000327	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—NFKBIA—psoriasis	1.81e-05	0.000325	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—NFKBIA—psoriasis	1.81e-05	0.000325	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—JUN—psoriasis	1.77e-05	0.000319	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CXCL8—psoriasis	1.76e-05	0.000317	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—APOE—psoriasis	1.75e-05	0.000315	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PPARG—psoriasis	1.74e-05	0.000313	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—NFKB1—psoriasis	1.71e-05	0.000307	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—IL6—psoriasis	1.67e-05	0.000301	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—CAT—psoriasis	1.65e-05	0.000297	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CD4—psoriasis	1.64e-05	0.000296	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—JUN—psoriasis	1.64e-05	0.000295	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—NFKB1—psoriasis	1.58e-05	0.000284	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—VEGFA—psoriasis	1.55e-05	0.000279	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—STAT3—psoriasis	1.53e-05	0.000276	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PPARG—psoriasis	1.52e-05	0.000274	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TYK2—psoriasis	1.51e-05	0.000272	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—CAT—psoriasis	1.49e-05	0.000268	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—TYK2—psoriasis	1.48e-05	0.000267	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TYK2—psoriasis	1.48e-05	0.000267	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—VEGFA—psoriasis	1.43e-05	0.000258	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—TP53—psoriasis	1.43e-05	0.000257	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—STAT3—psoriasis	1.42e-05	0.000255	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—CAT—psoriasis	1.41e-05	0.000254	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—TP53—psoriasis	1.39e-05	0.00025	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CXCL8—psoriasis	1.32e-05	0.000237	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—IL6—psoriasis	1.3e-05	0.000235	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—CAT—psoriasis	1.29e-05	0.000233	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CXCL8—psoriasis	1.29e-05	0.000232	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CXCL8—psoriasis	1.29e-05	0.000232	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—APOE—psoriasis	1.28e-05	0.000231	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—STAT3—psoriasis	1.27e-05	0.000229	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—IL6—psoriasis	1.25e-05	0.000225	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—IL6—psoriasis	1.23e-05	0.000221	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—IL6—psoriasis	1.23e-05	0.000221	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—JUN—psoriasis	1.22e-05	0.00022	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—CAT—psoriasis	1.2e-05	0.000217	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—JUN—psoriasis	1.2e-05	0.000216	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—JUN—psoriasis	1.2e-05	0.000216	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—NFKB1—psoriasis	1.18e-05	0.000212	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—TP53—psoriasis	1.17e-05	0.000211	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—APOE—psoriasis	1.16e-05	0.000208	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—NFKB1—psoriasis	1.15e-05	0.000208	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—NFKB1—psoriasis	1.15e-05	0.000208	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PPARG—psoriasis	1.12e-05	0.000201	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—APOE—psoriasis	1.09e-05	0.000197	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—TP53—psoriasis	1.08e-05	0.000195	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—IL6—psoriasis	1.07e-05	0.000193	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—VEGFA—psoriasis	1.07e-05	0.000193	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—STAT3—psoriasis	1.06e-05	0.000191	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—VEGFA—psoriasis	1.05e-05	0.000188	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—VEGFA—psoriasis	1.05e-05	0.000188	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—STAT3—psoriasis	1.04e-05	0.000187	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—STAT3—psoriasis	1.04e-05	0.000187	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PPARG—psoriasis	1.01e-05	0.000181	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—APOE—psoriasis	1e-05	0.000181	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—IL6—psoriasis	9.89e-06	0.000178	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.82e-06	0.000177	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PPARG—psoriasis	9.54e-06	0.000172	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—APOE—psoriasis	9.35e-06	0.000168	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CARM1—psoriasis	9.15e-06	0.000165	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—IL6—psoriasis	8.89e-06	0.00016	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PPARG—psoriasis	8.74e-06	0.000157	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.56e-06	0.000154	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PPARG—psoriasis	8.14e-06	0.000147	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TP53—psoriasis	8.08e-06	0.000145	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—TP53—psoriasis	7.91e-06	0.000142	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TP53—psoriasis	7.91e-06	0.000142	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—IL6—psoriasis	7.4e-06	0.000133	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—IL6—psoriasis	7.24e-06	0.00013	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—IL6—psoriasis	7.24e-06	0.00013	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CAT—psoriasis	5.63e-06	0.000101	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—APOE—psoriasis	4.38e-06	7.88e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PPARG—psoriasis	3.81e-06	6.86e-05	CbGpPWpGaD
